Use of the R-enantiomers of N-propargyl 1-aminoindan compounds for treating Parkinson's disease.
US5453446A · kind A · utility
51Cited by
4References
20Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jun 7, 1994 |
| Grant date | Sep 26, 1995 |
| Priority date | — |
| Expiry date | Jun 7, 2014 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07C2602/08
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
R(+)-N-p-opargyl-1-aminoindan, its preparation and use and pharmaceutical compositions containing it. The novel compound was found to be useful for the treatment of human patients for Parkinson's disease, memory disorders, dementia of the Alzheimer type (DAT), depression and the hyperactive syndrome.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.